SLP - Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI
2024-02-01 15:27:39 ET
Summary
- Today, we circle back on Simulations Plus, Inc., a health information services company focused on drug discovery and development software.
- Analysts have reissued Buy ratings on the stock, but the high valuation and potential competition from generative AI are concerns.
- An updated analysis around Simulations Plus follows in the paragraphs below.
Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AIFrom my own experience I know that the cruelest thing is to make a person doubt his own reality ..."? Yevgeny Zamyatin.